FDA Approval Alert: The Need-to-Know | Pembrolizumab/Chemotherapy in Advanced/Recurrent Endometrial Carcinoma

In June 2024, the FDA approved pembrolizumab plus carboplatin and paclitaxel for patients with primary advanced or recurrent endometrial carcinoma.

Patients with primary advanced/recurrent endometrial carcinoma may now receive pembrolizumab plus chemotherapy as indicated by the FDA.
Pembrolizumab/Chemo Receives OK From FDA in Advanced Endometrial Cancer
Article
Jun 17, 2024 5:02 PM
Patients with primary advanced/recurrent endometrial carcinoma may now receive pembrolizumab plus chemotherapy as indicated by the FDA.